Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director · Chief Executive Officer | August 21, 2019 | August 23, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
KYNTRA BIO, INC.
Report date August 21, 2019 · Filed August 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,326,612 |
Ending reported balance
After 2019-08-22 transaction · row 6
5 source rows · reconciled sequenceRow 1 · 2019-08-21 · Exercise / conversion · Acquired 6,834 · Balance 2,356,578 Row 2 · 2019-08-21 · Sale · Disposed 18,400 · Balance 2,338,178 F1: Shares sold pursuant to a 10b5-1 plan. F2: The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 4 · 2019-08-22 · Exercise / conversion · Acquired 6,834 · Balance 2,345,012 Row 5 · 2019-08-22 · Sale · Disposed 17,100 · Balance 2,327,912 F1: Shares sold pursuant to a 10b5-1 plan. F4: The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Row 6 · 2019-08-22 · Sale · Disposed 1,300 · Balance 2,326,612 F1: Shares sold pursuant to a 10b5-1 plan. F5: The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Partnership | 45,656 |
Reported balance
After 2019-08-21 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2019-08-21 · Sale · Disposed 1,418 · Balance 45,656 F1: Shares sold pursuant to a 10b5-1 plan. F3: The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | IndirectBy Family Partnership | 44,238 |
Reported balance
After 2019-08-22 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2019-08-22 · Sale · Disposed 1,418 · Balance 44,238 F1: Shares sold pursuant to a 10b5-1 plan. F6: The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2020-06-09 | Direct | 184,536 |
Reported balance
After 2019-08-21 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-08-21 · Exercise / conversion · Disposed 6,834 · Balance 184,536 F8: Fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2020-06-09 | Direct | 177,702 |
Reported balance
After 2019-08-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-08-22 · Exercise / conversion · Disposed 6,834 · Balance 177,702 F8: Fully vested. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 20,000 |
Reported balance
Holding disclosure · report date 2019-08-21 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 20,000 |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 60,946 |
Reported balance
Holding disclosure · report date 2019-08-21 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 60,946 F7: The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold pursuant to a 10b5-1 plan.
F2: The shares were sold at prices ranging from $44.54 to $45.12. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: The shares were sold at prices ranging from $44.51 to $45.115. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4: The shares were sold at prices ranging from $43.46 to $44.38. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F5: The shares were sold at prices ranging from $44.61 to $44.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F6: The shares were sold at prices ranging from $43.47 to $43.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F7: The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
F8: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 02, 2018 Filed May 4, 2018 21:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,320 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-028151 · doc4.xml · derivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 402,461 Underlying: Common Stock · 10,320 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested. Read SEC document |
| May 02, 2018 Filed May 4, 2018 21:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 918 | $47.32 | $43,439.76 |
DisclosureSEC source: 0001209191-18-028151 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 114,072 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $47.025 to $47.575. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 02, 2018 Filed May 4, 2018 21:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,900 | $47.33 | $894,537.00 |
DisclosureSEC source: 0001209191-18-028151 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,897,593 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $46.75 to $47.65. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 02, 2018 Filed May 4, 2018 21:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,320 | $3.60 | $37,152.00 |
DisclosureSEC source: 0001209191-18-028151 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,916,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,320 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-025652 · doc4.xml · derivative · entry 12 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 412,781 Underlying: Common Stock · 10,320 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 918 | $48.60 | $44,614.80 |
DisclosureSEC source: 0001209191-18-025652 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 114,990 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $48.15 to $49.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 800 | $49.22 | $39,376.00 |
DisclosureSEC source: 0001209191-18-025652 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,906,173 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $49.15 to $49.40. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,100 | $48.68 | $881,108.00 |
DisclosureSEC source: 0001209191-18-025652 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,906,973 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $48.15 to $49.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,320 | $3.60 | $37,152.00 |
DisclosureSEC source: 0001209191-18-025652 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,925,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2018 Filed Apr 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,320 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-025652 · doc4.xml · derivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,101 Underlying: Common Stock · 10,320 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| April 17, 2018 Filed Apr 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 918 | $48.54 | $44,559.72 |
DisclosureSEC source: 0001209191-18-025652 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 115,908 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $48.20 to $48.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 17, 2018 Filed Apr 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 13,700 | $48.59 | $665,683.00 |
DisclosureSEC source: 0001209191-18-025652 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,914,753 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $48.40 to $48.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 17, 2018 Filed Apr 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 5,200 | $47.94 | $249,288.00 |
DisclosureSEC source: 0001209191-18-025652 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,928,453 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $47.40 to $48.35. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 17, 2018 Filed Apr 20, 2018 00:37 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,320 | $3.60 | $37,152.00 |
DisclosureSEC source: 0001209191-18-025652 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,933,653 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 05, 2018 Filed Apr 6, 2018 23:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,320 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-024267 · doc4.xml · derivative · entry 15 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 433,421 Underlying: Common Stock · 10,320 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Fully vested. Read SEC document |
| April 05, 2018 Filed Apr 6, 2018 23:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 300 | $46.10 | $13,830.00 |
DisclosureSEC source: 0001209191-18-024267 · doc4.xml · nonDerivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 116,826 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F10 · price: The shares were sold at prices ranging from $46.10 to $46.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2018 Filed Apr 6, 2018 23:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 618 | $45.06 | $27,847.08 |
DisclosureSEC source: 0001209191-18-024267 · doc4.xml · nonDerivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 117,126 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F9 · price: The shares were sold at prices ranging from $45.00 to $45.35. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2018 Filed Apr 6, 2018 23:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 8,400 | $46.20 | $388,080.00 |
DisclosureSEC source: 0001209191-18-024267 · doc4.xml · nonDerivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,923,333 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F8 · price: The shares were sold at prices ranging from $46.05 to $46.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2018 Filed Apr 6, 2018 23:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 10,500 | $45.13 | $473,865.00 |
DisclosureSEC source: 0001209191-18-024267 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,931,733 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $45.00 to $45.95. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 05, 2018 Filed Apr 6, 2018 23:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,320 | $3.60 | $37,152.00 |
DisclosureSEC source: 0001209191-18-024267 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,942,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 23:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,320 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-024267 · doc4.xml · derivative · entry 14 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443,741 Underlying: Common Stock · 10,320 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Fully vested. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 23:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 218 | $46.59 | $10,156.62 |
DisclosureSEC source: 0001209191-18-024267 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 117,744 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $46.40 to $46.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 23:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 700 | $45.36 | $31,752.00 |
DisclosureSEC source: 0001209191-18-024267 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 117,962 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $45.00 to $45.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 23:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,000 | $46.68 | $46,680.00 |
DisclosureSEC source: 0001209191-18-024267 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,931,913 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $46.55 to $46.80. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 23:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 7,800 | $45.97 | $358,566.00 |
DisclosureSEC source: 0001209191-18-024267 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,932,913 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $45.55 to $46.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 23:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 10,100 | $45.16 | $456,116.00 |
DisclosureSEC source: 0001209191-18-024267 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,940,713 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $44.55 to $45.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 04, 2018 Filed Apr 6, 2018 23:55 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 10,320 | $3.60 | $37,152.00 |
DisclosureSEC source: 0001209191-18-024267 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,950,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 21, 2018 Filed Mar 22, 2018 23:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,042 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-021337 · doc4.xml · derivative · entry 12 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,061 Underlying: Common Stock · 9,042 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| March 21, 2018 Filed Mar 22, 2018 23:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 918 | $51.13 | $46,937.34 |
DisclosureSEC source: 0001209191-18-021337 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,662 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $50.65 to $51.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 21, 2018 Filed Mar 22, 2018 23:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 900 | $51.63 | $46,467.00 |
DisclosureSEC source: 0001209191-18-021337 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,940,493 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F6 · price: The shares were sold at prices ranging from $51.60 to $51.70. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 21, 2018 Filed Mar 22, 2018 23:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 18,000 | $51.17 | $921,060.00 |
DisclosureSEC source: 0001209191-18-021337 · doc4.xml · nonDerivative · entry 6 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,941,393 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F5 · price: The shares were sold at prices ranging from $50.575 to $51.55. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 21, 2018 Filed Mar 22, 2018 23:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 9,042 | $3.60 | $32,551.20 |
DisclosureSEC source: 0001209191-18-021337 · doc4.xml · nonDerivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,959,393 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 23:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,042 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-021337 · doc4.xml · derivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 463,103 Underlying: Common Stock · 9,042 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 23:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 918 | $50.71 | $46,551.78 |
DisclosureSEC source: 0001209191-18-021337 · doc4.xml · nonDerivative · entry 4 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 119,580 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F4 · price: The shares were sold at prices ranging from $50.20 to $50.875. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 23:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 3,968 | $51.02 | $202,447.36 |
DisclosureSEC source: 0001209191-18-021337 · doc4.xml · nonDerivative · entry 3 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,950,351 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F3 · price: The shares were sold at prices ranging from $51.00 to $51.15. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 23:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 14,932 | $50.64 | $756,156.48 |
DisclosureSEC source: 0001209191-18-021337 · doc4.xml · nonDerivative · entry 2 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,954,319 F1 · shares: Shares sold pursuant to a 10b5-1 plan. F2 · price: The shares were sold at prices ranging from $50.10 to $50.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 20, 2018 Filed Mar 22, 2018 23:19 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 9,042 | $3.60 | $32,551.20 |
DisclosureSEC source: 0001209191-18-021337 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,969,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 22:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $53.75 | $0.00 |
DisclosureSEC source: 0001209191-18-020342 · doc4.xml · derivative · entry 5 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2028-03-14 F3 · derivative.exercise_date: Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in equal amounts quarterly thereafter for the following three years. Read SEC document |
| March 14, 2018 Filed Mar 16, 2018 22:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-020342 · doc4.xml · nonDerivative · entry 1 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,960,209 F1 · shares: Represents the grant of restricted stock units. Twenty-five percent of the restricted stock units vest on March 6, 2019, and the remainder vests in equal amounts quarterly thereafter for the following three years. Read SEC document |
| March 08, 2018 Filed Mar 9, 2018 01:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,314 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-18-018362 · doc4.xml · derivative · entry 19 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,145 Underlying: Common Stock · 3,314 shares Expires 2019-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: Fully vested. Read SEC document |
| March 08, 2018 Filed Mar 9, 2018 01:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,005 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001209191-18-018362 · doc4.xml · derivative · entry 18 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,005 shares Expires 2018-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: Fully vested. Read SEC document |
| March 08, 2018 Filed Mar 9, 2018 01:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 618 | $53.59 | $33,118.62 |
DisclosureSEC source: 0001209191-18-018362 · doc4.xml · nonDerivative · entry 14 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 120,498 F2 · shares: Shares sold pursuant to a 10b5-1 plan. F12 · price: The shares were sold at prices ranging from $53.20 to $54.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 08, 2018 Filed Mar 9, 2018 01:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 300 | $52.55 | $15,765.00 |
DisclosureSEC source: 0001209191-18-018362 · doc4.xml · nonDerivative · entry 13 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 121,116 F2 · shares: Shares sold pursuant to a 10b5-1 plan. F11 · price: The shares were sold at prices ranging from $52.05 to $52.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 08, 2018 Filed Mar 9, 2018 01:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 700 | $54.09 | $37,863.00 |
DisclosureSEC source: 0001209191-18-018362 · doc4.xml · nonDerivative · entry 12 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,890,209 F2 · shares: Shares sold pursuant to a 10b5-1 plan. F10 · price: The shares were sold at prices ranging from $54.00 to $54.10. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 08, 2018 Filed Mar 9, 2018 01:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 11,800 | $53.44 | $630,592.00 |
DisclosureSEC source: 0001209191-18-018362 · doc4.xml · nonDerivative · entry 11 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,890,909 F2 · shares: Shares sold pursuant to a 10b5-1 plan. F9 · price: The shares were sold at prices ranging from $53.05 to $53.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 08, 2018 Filed Mar 9, 2018 01:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 6,400 | $52.74 | $337,536.00 |
DisclosureSEC source: 0001209191-18-018362 · doc4.xml · nonDerivative · entry 10 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,902,709 F2 · shares: Shares sold pursuant to a 10b5-1 plan. F8 · price: The shares were sold at prices ranging from $52.05 to $53.00. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 08, 2018 Filed Mar 9, 2018 01:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 3,314 | $3.60 | $11,930.40 |
DisclosureSEC source: 0001209191-18-018362 · doc4.xml · nonDerivative · entry 9 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,909,109 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2018 Filed Mar 9, 2018 01:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionCommon Stock | 7,005 | $2.35 | $16,461.75 |
DisclosureSEC source: 0001209191-18-018362 · doc4.xml · nonDerivative · entry 8 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,905,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 01:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,265 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001209191-18-018362 · doc4.xml · derivative · entry 17 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,005 Underlying: Common Stock · 10,265 shares Expires 2018-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: Fully vested. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 01:42 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 218 | $53.91 | $11,752.38 |
DisclosureSEC source: 0001209191-18-018362 · doc4.xml · nonDerivative · entry 7 Neff Thomas B · CIK 0001623238 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Partnership Disclosed balance after: 121,416 F2 · shares: Shares sold pursuant to a 10b5-1 plan. F7 · price: The shares were sold at prices ranging from $53.55 to $54.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.